Idenix Pharmaceuticals (IDIX)

[DewDiligence]

IDIX was always on a royalty arrangement outside the US and the top-5 EU countries (the “RoW” zone in #msg-24405569), and the royalty schedule presumably didn’t change in the restructuring.

In the top-5 EU countries, the restructuring means that IDIX will do better in the near-term and medium-term future, but somewhat worse in the long term if sales really take off.